Lilly CEO Says Foundayo Captures One in Three New U.S. Oral Weight Loss Starts

Eli Lilly CEO Dave Ricks said Monday that Foundayo now accounts for one in three new oral weight loss drug starts in the United States, with the pill gaining share weekly. Ricks made the remarks in an exclusive CNBC interview. Foundayo entered the U.S. market in April and posted $98 million in second-quarter revenue. Lilly said it held about 61% of the overall weight loss and diabetes market in the second quarter. The start of Medicare obesity drug coverage in July is seen as a catalyst for further uptake, and additional country rollouts are planned for later this year. The comments came as Lilly broke ground on a $6.5 billion manufacturing facility at Generation Park in Houston, Texas, expected to be operational by 2030. The plant will produce core chemical components for Lilly's cardiometabolic, oncology, immunology and neuroscience treatments. The Houston site is part of a broader push; Lilly has pledged more than $50 billion in manufacturing investment since 2020.